More importantly, our in vivo data also demonstrated that AZD1775, at an oral dose of 60 mg/kg/day, greatly attenuated the tumor growth of xenografted KYSE150 cells and significantly suppressed the phospho-CDK1 (Y15) expression, indicating that AZD1775 might be a potential therapeutic drug for the treatment of ESCC. Here, CDK1 is linked to neoplasm.